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Summary
Although echocardiography-derived tricuspid regurgitant jet velocity (TRV) is associated with
increased mortality in sickle cell disease (SCD), its rate of increase and predictive markers of its
progression are unknown. We evaluated 55 subjects (median age: 38 years, range: 20 – 65 years)
with at least 2 measurable TRVs, followed for a median of 4.5 years (range: 1.0 – 10.5 years) in a
single-centre, prospective study. Thirty-one subjects (56%) showed an increase in TRV, while 24
subjects (44%) showed no change or a decrease in TRV. A linear mixed effects model indicated
an overall rate of increase in the TRV of 0.02 m/s per year (p = 0.023). The model showed that
treatment with hydroxycarbamide was associated with an initial TRV that was 0.20 m/s lower than
no such treatment (p = 0.033), while treatment with angiotensin converting enzyme inhibitors and
inhibitors/ angiotensin receptor blockers was associated with an increase in the TRV (p = 0.006).
In summary, although some patients have clinically meaningful increases, the overall rate of TRV
increase is slow. Treatment with hydroxycarbamide may decrease the progression of TRV.
Additional studies are required to determine the optimal frequency of screening echocardiography
and the effect of therapeutic interventions on the progression of TRV in SCD.
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Introduction
The prevalence of echocardiography-defined pulmonary hypertension (subsequently referred
to as pulmonary hypertension [PHT] risk), based on a tricuspid regurgitant jet velocity
(TRV) ≥ 2.5 m/s, in adult patients with sickle cell disease (SCD) is approximately 30%
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(Ataga, et al 2004, Gladwin, et al 2004). Using the modified Bernoulli equation, the TRV
provides a calculated estimate of right ventricular and pulmonary artery systolic pressures
(PASP = 4TRV2 + estimated right atrial pressure) (Yock and Popp 1984). Although recent
studies suggest that echocardiography-assessed TRV may over-estimate the prevalence of
PHT (Fonseca, et al 2011, Parent, et al 2011), elevated TRV is recognized as an independent
predictor of mortality in SCD (Ataga, et al 2006, De Castro, et al 2008, Gladwin, et al 2004).
Because of this association with increased mortality, many authors have recommended
routine screening of SCD patients with Doppler echocardiography (Ataga, et al 2006, De
Castro, et al 2008, Gladwin, et al 2004). However, as the rate of increase of the TRV is
unknown, the optimal frequency of screening echocardiography remains unknown. In this
study, we have evaluated the rate of increase of TRV and assessed the predictive markers of
such increase in adult patients with SCD.
Materials and Methods
Subjects and Study Design
This study was conducted as a single-centre, prospective evaluation of the rate of increase of
echocardiography-derived TRV in adult patients with SCD. The study subjects represent a
cohort of patients followed at the Sickle Cell Clinic at the University of North Carolina
(UNC), Chapel Hill. The data were collected as part of a study to investigate the
pathophysiology and natural history of PHT in SCD (Ataga, et al 2006). Consecutive SCD
patients seen in the clinic for routine follow up, who agreed to participate, were evaluated.
Subjects who had an echocardiogram on more than one occasion during the course of the
study and had more than one measurable TRV were evaluated. The effect of select
interventions on TRV was assessed by a review of subject charts. Interventions were for a
minimum of 12 months duration and included: treatment with hydroxycarbamide (also
known as hydroxyurea), angiotensin converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARB); chronic red blood cell (RBC) transfusion; chronic oxygen therapy;
and/or PHT-specific therapy. Each subject was studied in the non-crisis, “steady state,” and
had not had acute chest syndrome in the 4 weeks preceding enrollment, and had no evidence
of congestive heart failure. Written informed consent was obtained and the study was
approved by the Institutional Review Board at UNC, Chapel Hill.
Echocardiography
Transthoracic Doppler echocardiography was performed in all SCD patients using a
Hewlett-Packard 2500 Ultrasound System, with a 2.5/2.0 MHz ultrasound probe (Model
21215A) for recording continuous wave signals. Echocardiograms were interpreted by a
cardiologist blinded to all the patients’ data. Multiple views (apical four-chamber, short axis
and tricuspid inflow) were obtained to record optimal tricuspid flow signals. The TRV was
measured using continuous wave Doppler echocardiography on at least three waveforms
with well-defined velocity envelopes and an average value (expressed to the nearest 0.1 m/s)
used for data analysis.
Statistical Analysis
Data were dichotomized to evaluate for associations between increased TRV (an increase of
at least 0.1 m/s) compared with no increase in TRV (decreased TRV and no change in
TRV). Associations between increased TRV and clinical and laboratory covariates were
obtained using Wilcoxon rank sum tests for continuous variables and Fishers Exact Test for
dichotomous variables. Linear mixed effects models were used to analyse the rate of
increase of TRV and included both a random intercept and time effect for each subject.
Linear mixed models were used because the TRV assessments were not obtained at fixed
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intervals in all the study subjects. Reported p-values are considered ‘nominal’ and are for
individual tests, unadjusted for multiple comparisons because of the exploratory nature of
this study. Statistical analyses were performed using R statistical software (www.r-
project.org).
Results
One hundred and sixty-four subjects were evaluated in this study. Of the 76 subjects who
had more than one echocardiographic assessment, 9 had no measurable TRV and 12 had
only one measurable value. Fifty five subjects (30 female, 25 male; SS – 46, SC – 4, Sβ0 –
3, Sβ+ - 2), with a median age of 38.0 years (range: 20 – 65 years), had at least 2 measurable
TRVs and were followed for a median of 4.5 years (range 1.0 – 10.5 years) (Table I). Two
measurable TRVs were obtained in 30 subjects, 3 measurable values were obtained in 16
subjects, 4 measurable values were obtained in 7 subjects, and 5 measurable values were
obtained in 2 subjects. Thirty-one subjects (56%) showed an increase in TRV (median
baseline: 2.5 m/s, range: 1.8 – 3.3), while 24 subjects (44%) showed no change or a decrease
in TRV (median baseline: 2.5 m/s, range: 2.0 – 3.2). Of the 22 subjects who had a TRV
value > 2.5 m/s at baseline, 12 (54.5%) had subsequent increases in the TRV and 10 (45.5%)
did not. Of the 33 subjects with a TRV ≤ 2.5 at baseline, 19 (57.6%) had subsequent
increases in the TRV and 14 (42.4%) did not. The proportion of subjects with an increase in
TRV in each of these groups were not statistically different (p = 1.0, Fishers Exact Test). A
linear mixed effects model estimated an initial TRV of 2.5 m/s (observed baseline TRV
ranged from 1.8 to 3.3 m/s) and a rate of increase of 0.02 m/s/year (p = 0.023) for all the
study subjects (Figure 1). For those subjects with an increase in TRV, the model predicted a
rate of increase of 0.07 m/s/year. While subjects with an initial TRV ≥ 2.5 m/s were
predicted to have an increase over time that was slightly greater than those with an initial
TRV < 2.5 m/s, this difference was not statistically significant (p = 0.68). Seven subjects
were noted to have an initial TRV of 3.0 m/s or higher, with 15 subjects found to have at
least one TRV value of 3.0 m/s during the course of the study (Figure 1). In addition, there
were 18 subjects with initial TRVs of between 2.5 and 2.8 m/s, 8 (44.4 %) of whom
(median: 2.65 m/s, range: 2.5 – 2.8) experienced subsequent increases in their TRV values
to ≥ 3.0 m/s during the course of the study.
For study subjects not receiving any therapeutic interventions for SCD-related complications
at study enrollment, the model estimated an initial TRV of 2.6 m/s, and a rate of decrease in
TRV of 0. 01 m/s/year (p = 0.79). The study subjects on hydroxycarbamide at enrollment (N
= 26) were found to have an initial TRV that was 0.2 m/s lower than those not on
hydroxycarbamide (p = 0.033), with a predicted rate of increase of 0.018 m/s/year for
subjects on hydroxycarbamide compared to 0.025 m/s/year for subjects not on
hydroxycarbamide (p = 0.72). The study subjects on hydroxycarbamide for at least 12
months during the study (N = 33) were predicted to have an increase in the TRV of 0.01 m/
s/year, not significantly different from the 0.04 m/s/year increase predicted for subjects not
on hydroxycarbamide (p = 0.19). When hydroxycarbamide status was treated as a time-
varying covariate, no significant differences were observed in the TRV or rate of increase of
TRV when subjects on hydroxycarbamide were compared to those not on such therapy (data
not shown). The study subjects on ACE inhibitors/ARBs at enrollment (N = 6) were found
to have an initial TRV that was 0.06 m/s higher than subjects not on such therapies (p =
0.69). In addition, the study subjects on ACE inhibitors/ARBs for at least 12 months during
the study (N = 13) were predicted to have an increase in TRV that was 0.06 m/s/year greater
than those not on ACE inhibitors/ARBs (p = 0.006). When the status of ACE inhibitors/
ARBs was treated as a time-varying covariate, subjects on ACE inhibitors/ARBs were found
to have a TRV that was 0.03 m/s lower than subjects not on such therapies (p = 0.75), but
were predicted to have an increase in TRV of 0.07 m/s/year more than subjects not on ACE
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inhibitors/ARBs (p = 0.03). The individual effects of chronic RBC transfusion (N = 2),
PHT-specific treatments (N = 2) and chronic oxygen therapy (N = 5) were not assessed.
There was a significant difference in the level of direct bilirubin (p = 0.05) when subjects
with an increase in TRV were compared to those with no change or a decrease in the TRV.
No differences were observed in other evaluated laboratory variables (Table II). Six of 31
subjects with an increase in TRV died compared to 1 of 24 subjects with no increase in the
TRV, but the difference did not achieve statistical significance (p = 0.12) (Table III).
Furthermore, when the deceased subjects in both groups were compared using a Kaplan-
Meier survival analysis, no statistically significant difference was observed (p = 0.09, log
rank test) (Figure 2). Of the 6 deceased subjects in the increased TRV group, 2 were on
hydroxycarbamide and 4 were not. The 1 deceased subject in the no increase group was on
hydroxycarbamide. Discussion:
The utility of screening echocardiography in SCD-associated PHT remains controversial
(Bunn, et al 2010, Hassell 2010). This is due to the modest correlation that has been
observed between PASP estimated on echocardiography and values measured on right heart
catheterization (Fonseca, et al 2011, Parent, et al 2011). A recent multicentre study found no
evidence of PHT following right heart catheterization in 72 of 96 patients with elevated
TRV on echocardiography (Parent, et al 2011), suggesting that a cut-off value of 2.5 m/s on
Doppler echocardiography may be too low for defining PHT in patients with SCD. In
addition, while patients are frequently treated with agents approved for pulmonary arterial
hypertension, there are, to date, no proven therapies for SCD-associated PHT (Barst, et al
2010, Machado, et al 2011). However, as TRV is a recognized marker of increased mortality
in SCD (Ataga, et al 2006, De Castro, et al 2008, Gladwin, et al 2004), knowledge of its rate
of change could help determine the frequency of screening echocardiograms in this
population. In our patient cohort, we found that TRV increases with time, albeit at a slow
rate. With this predicted slow rate of increase in the TRV, there does not appear to be a
reason to obtain yearly screening echocardiograms on all patients as an annual increase of
0.02 m/s/year is not clinically meaningful. However, a subset of patients with baseline TRV
values of between 2.5 m/s and 2.8 m/s appear to have more clinically meaningful increases
in their TRVs and may benefit from more frequent echocardiographic screenings, followed
by right heart catheterization if the TRV is at least 3.0 m/s or if they develop symptoms and/
or signs suggestive of PHT. Recent reports suggest that compared to a value of 2.5 m/s, a
TRV greater than 2.9 m/s has a greater predictive value for right heart catheterization-
confirmed PHT (Mehari, et al 2012, Parent, et al 2011). Indeed, 4 of the 7 subjects with
initial TRV of ≥ 3.0 m/s in our cohort who agreed to undergo a right heart catheterization
had PHT (pulmonary arterial hypertension in 2 subjects and pulmonary venous hypertension
in 2 subjects).
Although most evaluated variables were not associated with an increase in TRV, the number
of subjects in our study was relatively small. The significance of the association of direct
bilirubin with an increase in TRV is uncertain. While not statistically significant, there
appeared to be a higher risk of death in subjects who experienced an increase in their TRVs.
This finding further highlights the increased risk of mortality with increased TRV in SCD.
The significantly lower baseline TRV and the lower rate of increase in TRV in patients on
hydroxycarbamide suggest that this therapeutic intervention may be beneficial in SCD-
associated PHT. There are no controlled studies in this setting (Ataga, et al 2006, Olnes, et
al 2009, Pashankar, et al 2009), but hydroxycarbamide may provide benefit to patients with
SCD by: decreasing haemolysis with increases in levels of fetal haemoglobin (Carache, et al
1995); modulating endothelial function by decreasing levels of soluble vascular cell
adhesion molecule-1 (Kato, et al 2005, Saleh, et al 1999); decreasing the release of the
vasoconstrictor peptide, endothelin-1 (Brun, et al 2003); and increasing the generation of
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nitric oxide (Gladwin, et al 2002, Glover, et al 1999). While patients receive
hydroxycarbamide as treatment for severe haemolytic anaemia, SCD patients are more
commonly begun on this treatment to decrease the frequency of acute painful episodes and
acute chest syndrome. As both acute painful episodes and acute chest syndrome are thought
to be vaso-occlusive complications that are associated with a lower degree of haemolysis
(Kato, et al 2007), and may not be associated with PHT risk (Ataga, et al 2006, Gladwin, et
al 2004), it is also conceivable that many patients begun on hydroxycarbamide for these
indications may have lower TRVs as well as lower rates of progression compared to patients
with higher degrees of haemolysis. However, any effects of hydroxycarbamide on SCD-
associated PHT will be best defined in an adequately controlled clinical trial. The
association of ACE inhibitors/ARBs therapy with an increase in TRV in our patient cohort
was unexpected, although this finding is limited by the small number of patients on ACE
inhibitors/ARBs in our patient cohort. Furthermore, with the known association of
proteinuria and PHT (Ataga, et al 2010, De Castro, et al 2008), combined with the frequent
use of ACE inhibitors/ARBs as treatment for proteinuria in SCD (Falk, et al 1992), this
finding is not particularly surprising. While activation of the ACE-AngII-AT1R axis of the
renin-angiotensin system may contribute to the pathophysiology of pulmonary arterial
hypertension (Marshall 2003), therapy with ACE inhibitors/ARBs in patients with PHT has
produced mixed results (Bradford, et al 2010). Despite these findings, this study was not
designed to evaluate the effect of any therapeutic interventions. In addition, adherence to the
various therapies was not evaluated and patients were often receiving more than one
intervention during the period of follow-up, thus limiting any assessment of the effect of
individual agents.
In summary, although this study was limited by the relatively small size of our patient
cohort and our inability to obtain a measurable TRV in some participants, we found that
TRV increases with time, albeit slowly. The rate of increase of the TRV appears to be even
slower in patients being treated with hydroxycarbamide. As a subset of patients may
experience more clinically meaningful increases in TRV, decisions about the frequency of
screening should be individualized. Additional studies are needed to evaluate the rate of
increase of TRV as well as the predictive markers of such increase in adult patients with
SCD.
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Change in tricuspid regurgitant jet velocity (TRV) over time in all subjects (solid line), with
no intervention (broken line) and on hydroxycarbamide (dotted line). At baseline, all
patients had an estimated TRV of 2.5 m/s, with an estimated rate of increase of 0.02 m/s per
year. At baseline, patients without any interventions had an estimated TRV of 2.6 m/s, with
an estimated rate of increase of 0.01 m/s per year. At baseline, patients on
hydroxycarbamide for at least 12 months prior to enrollment had an estimated TRV of 2.4
m/s, with an estimated rate of increase of 0.01 m/s per year.
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Kaplan-Meier Survival Plot comparing the subjects with an increase in tricuspid regurgitant
jet velocity (TRV) and those with a decreased or no change in TRV. There was no
statistically significant difference when both groups were compared (p = 0.09, log rank test).
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Table I
Demographic and Laboratory Characteristics of Study Subjects
Variable Number of Subjects Median (min, max) or Number (%)
Age (years) 55 38 (20, 65)
Gender 55
 (Male) 25 (45%)
 (Female) 30 (55%)
Genotype 55
 (SS) 46 (83.6%)
 (SC) 4 (7.3)
 (Sβ0) 3 (5.5%)
 (Sβ+) 2 (3.6)
Weight (kg) 55 69.6 (47.2, 176.0)
Time between echocardiography assessments (years) 55 2.9 (1.0, 8.3)
White blood cell count (x 109/l) 55 9.1 (4.3, 15.4)
Haemoglobin (g/l) 55 87 (38, 128)
Platelet count (x 109/l) 54 372 (160, 1054)
Reticulocyte count (%) 52 7.0 (1.9, 24.0)
Fetal Haemoglobin (%) 55 6.1 (0.0, 32.6)
Use of hydroxycarbamide 55
 (No) 28 (51%)
 (Yes) 27 (49%)
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Table III
Association of Tricuspid Regurgitant Jet Velocity (TRV) with Clinical Variables
Variable
Increased in TRV Decreased or No Change in TRV p-Value
N N
Gender
Female 18 12 0.59
Male 13 12
Smoking Status
Yes 10 10 0.58
No 21 14
History of Leg Ulcer
Yes 9 8 0.78
No 22 16
History of Acute Chest Syndrome
Yes 25 17 0.53
No 6 7
Genotype
SS/Sβ0/SD 24 23 0.12
SC/Sβ+ 7 1
Number of Painful Episodes in Past Year
<3 8 5 0.67
≥3 4 4
History of Stroke
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